Skip to main content
Equibles

Elaine Sun

Board Member

Recursion Pharmaceuticals, Inc. (RXRX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Recursion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get RXRX alerts

About Elaine Sun

Elaine Sun is recorded as Board Member at Recursion Pharmaceuticals, Inc. (RXRX) since January 1, 2025. The newest filing on record that lists Elaine Sun as Board Member at Recursion Pharmaceuticals, Inc. (RXRX) is dated April 30, 2026. Earlier roles on record: CFO at Halozyme Therapeutics, Inc. (HALO) until February 2, 2022. Recursion Pharmaceuticals, Inc. reported in an 8-K filed March 18, 2025 that Elaine Sun was appointed Class III Director, effective March 15, 2025. Elaine Sun has spoken on 2 earnings calls across 1 company, most recently for Halozyme Therapeutics, Inc. on November 2, 2021. Recursion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Elaine Sun spoke on are classified in the Healthcare sector. Other leadership on record at Recursion Pharmaceuticals, Inc. includes Christopher C. Gibson (CEO and Board Member), Najat Khan (CEO), Najat Khan, Ph.D. (CEO and Board Member) and 7 others.

“On March 15, 2025, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”), upon the recommendation from its Nominating and Corporate Governance Committee (the “Nominating Committee”), increased the number of members of the Board from 8 to 10 and appointed each of Elaine Sun and Dr. Namandjé Bumpus to the Board, effective immediately.”
Recursion Pharmaceuticals, Inc. Form 8-K, filed March 18, 2025 · Read the filing

Elaine Sun on recent calls

“Before I begin, I'd like to again note that we now report key measures on a non-GAAP adjusted basis in addition to a GAAP basis, and also provide financial guidance on a non-GAAP basis.”
CFO, Halozyme Therapeutics, Inc. Q3 FY2021 Earnings Call ·
“Let me turn to Slide 8 for a review of our fourth quarter revenues. As Helen indicated, we again saw strong growth in the quarter, as our partners continued to execute on their commercial and development plans to establish subcutaneously delivered biologics in the US and globally.”
CFO, Halozyme Therapeutics, Inc. Q4 FY2020 Earnings Call ·

Affiliation history

Company network

Leadership on record at Recursion Pharmaceuticals, Inc.

Recent activity